CN103285011A - Application of Aspeverin in red blood cell increase drug preparation - Google Patents
Application of Aspeverin in red blood cell increase drug preparation Download PDFInfo
- Publication number
- CN103285011A CN103285011A CN2013102512828A CN201310251282A CN103285011A CN 103285011 A CN103285011 A CN 103285011A CN 2013102512828 A CN2013102512828 A CN 2013102512828A CN 201310251282 A CN201310251282 A CN 201310251282A CN 103285011 A CN103285011 A CN 103285011A
- Authority
- CN
- China
- Prior art keywords
- aspeverin
- red blood
- blood cell
- drug preparation
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a new use of a compound Aspeverin in the field of drug preparation. The present invention relates to an application of the Aspeverin in red blood cell increase drug preparation. According to the present invention, the use of the Aspeverin in low red blood cell treatment drug preparation is firstly disclosed, the skeleton belongs to a completely-new skeleton type, inhibition activity on the low red blood cell is strong, possibility that any revelation is provided by other compounds does not exist, the drug has prominent substantive characteristics, and significant progress is provided for prevention and treatment of the low red blood cell with the drug.
Description
Technical field
The present invention relates to the new purposes of compd A speverin, relate in particular to the application of Aspeverin in preparation rising erythrocyte medicine.
Background technology
The compd A speverin that the present invention relates to is one and delivered (Nai-Yun Ji in 2013, et al., Aspeverin, a New Alkaloid from an Algicolous Strain of Aspergillus versicolor.Organic Letters, 2013,10 (15), 2327 – 2329.) noval chemical compound, this chemical compound has brand-new framework types, present purposes only relates to and suppresses to swim vegeto-animal growth (Nai-Yun Ji, et al., Aspeverin, a New Alkaloid from an Algicolous Strain of Aspergillus versicolor.Organic Letters, 2013,10 (15), 2327 – 2329.), belong to open first for the purposes of the Aspeverin that the present invention relates in preparation rising erythrocyte medicine.
Summary of the invention
The objective of the invention is to provides the application of Aspeverin in preparation rising erythrocyte medicine according to not finding in the existing Aspeverin research that it has the present situation of the erythrocytic report that raises.
Described compd A speverin structure is shown in formula I:
Formula I
The purposes of the Aspeverin that the present invention relates in the low medicine thing of preparation treatment erythrocyte belongs to open first, because framework types belongs to brand-new framework types, and it lowly suppresses active unexpectedly strong for erythrocyte, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, be used for the low control of erythrocyte simultaneously and obviously have obvious improvement.
The specific embodiment
The preparation method of compd A speverin involved in the present invention is referring to document (Nai-Yun Ji, et al., Aspeverin, a New Alkaloid from an Algicolous Strain of Aspergillus versicolor.Organic Letters, 2013,10 (15), 2327 – 2329.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compd A speverin tablet involved in the present invention:
Get 5 and digest compound Aspeverin adding dextrin 195 grams, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compd A speverin capsule involved in the present invention:
Get 5 and digest compound Aspeverin and add starch 195 grams, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
The hemoposieis of Aspeverin:
One, Aspeverin is to the therapeutical effect of the mice that loses blood
Influence to the mice that loses blood: 40 of ICR mices, Nanjing Medical University's Experimental Animal Center, ♀ ♂ half and half is divided into 4 groups (n=10).Except the normal saline group, every mice of other group is got the blood survey again and all respectively organizes index from eye socket venesection 0.5ml behind the 24h, then continuous 1 week of gastric infusion, behind the last administration 1h, gets blood from the eye socket venous plexus and surveys These parameters with F-800 whole blood platelet analyser.
Table 1Aspeverin is to because of oligocythemic therapeutical effect due to losing blood
Compare with model group: * p＜0.05**p＜0.01
The result shows that the blood-letting mice is through taking the Aspeverin treatment after 7 days, and 2 administration groups compare respectively at model group, and its erythrocyte is significantly higher than model group, near the normal saline group.
Two, the cyclophosphamide of Aspeverin causes oligocythemic therapeutical effect
Preventive and therapeutic effect to the damage of mouse bone marrow cells hemopoietic function: 40 of ICR mices, Nanjing Medical University's Experimental Animal Center, ♀ ♂ dual-purpose, be divided into 4 groups (n=10), be normal saline group, modeling group, 1.2mg/kg group and 0.6mg/kg group, oral administration, every day 1 time.0th, other respectively organized mice lumbar injection cycli phosphate amine 80mg/kg respectively, continued administration then 3 days except the normal saline group on 5th, 10.1h after the last administration gets blood from the eye socket venous plexus, surveys erythrocyte, gets femur bone marrow counting nucleated cell number.
The erythrocytic influence of the table caused by cyclophosphamide of 2Aspeverin
Compare with the normal saline group: * p＜0.05**p＜0.01
The result shows, compares with the normal saline group, and cycli phosphate amine can make the mouse bone marrow cells damage, causes peripheral blood cells to descend, and the Aspeverin group compares with model group, all can obviously resist the red decline of cycli phosphate amine induced mice.
Three, oligocythemic therapeutical effect due to the benzene of Aspeverin
Influence to Induced Aplastic Anemia Mice: 48 of Kunming mouses, Nanjing Medical University's Experimental Animal Center, ♀ ♂ dual-purpose, be divided into 4 groups (n=12), except the normal saline group, other group mouse subcutaneous injection benzene 0.5ml/kg, continuous 12 days, the same day of modeling, oral administration simultaneously, every day 1 time, totally 18 days, 1h after the last administration, the eye socket venous plexus is got blood, survey erythrocyte, get femur bone marrow counting nucleated cell number.
Oligocythemic therapeutical effect due to the benzene of table 3Aspeverin
Compare with model group: * p＜0.05**p＜0.01
The result shows, 2 administration groups respectively at model group relatively all can obviously be resisted the erythrocytic decline of Induced Aplastic Anemia Mice due to the benzene.
Four, oligocythemic therapeutical effect due to the radiation of Aspeverin
Be the therapeutical effect of studying acute radiation sickness, observed the influence of the 6.5Gy irradiation of the Aspeverin mice hemopoietic recovery of various dose.
Oligocythemic therapeutical effect (the 10th day) due to the radiation of table 4Aspeverin
Compare with the modeling group: * p＜0.05**p＜0.01
The result shows, give be subjected to according to mice Aspeverin0.1 every day, 0.5 and the 2.0mg/kg treatment after, the recovery model of peripheral red blood cells is accelerated, and is the best with 2.0mg dosage group effect.
Conclusion: the Aspeverin erythrocyte that can significantly raise can be used for the preparation erythrocytic medicine that raises.
Claims (1)
1.Aspeverin the application in preparation rising erythrocyte medicine, described compd A speverin structure is shown in formula I:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102512828A CN103285011A (en) | 2013-06-22 | 2013-06-22 | Application of Aspeverin in red blood cell increase drug preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102512828A CN103285011A (en) | 2013-06-22 | 2013-06-22 | Application of Aspeverin in red blood cell increase drug preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103285011A true CN103285011A (en) | 2013-09-11 |
Family
ID=49086902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102512828A Pending CN103285011A (en) | 2013-06-22 | 2013-06-22 | Application of Aspeverin in red blood cell increase drug preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103285011A (en) |
-
2013
- 2013-06-22 CN CN2013102512828A patent/CN103285011A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| NAI-YUN JI,ET AL: "Aspeverin,a New Alkaloid from an Algicolous Strain of Aspergillus versicolor", 《ORGANIC LETTERS》 * |
| 毛逢银等: "细胞催熟剂-LR生物碱-表面活性剂三元复合物治疗家兔再障性贫血初探", 《四川理工学院学报自然科( 学版)》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103271913A (en) | Application of Myriberine A in preparing thrombocyte-increasing medicines | |
| CN102988380B (en) | Application of Houttuynoid B in preparation of medicine for rising white blood cells | |
| CN103285011A (en) | Application of Aspeverin in red blood cell increase drug preparation | |
| CN103271917A (en) | Application of Myriberine A in preparing erythrocyte-increasing medicines | |
| CN102872036A (en) | Application of Gypensapogenin A in medicament for increasing level of red blood cells | |
| CN102988392B (en) | Application of Houttuynoid B in preparation of medicine for rising red blood cells | |
| CN103462956B (en) | Application of Nardoaristolones A in preparation of medicaments for increasing erythrocytes | |
| CN103720686B (en) | Trigoxyphin K is raising the application in erythrocyte medicine | |
| CN103356648B (en) | Chukrasone A raises the application in erythrocytic medicine in preparation | |
| CN105456272A (en) | Application of Biscarpamontamine A in preparing medicine for increasing red blood cells | |
| CN103463105A (en) | Application of Phyllanthoid A in preparing medicament for increasing erythrocytes | |
| CN103417549B (en) | Application of compound Kadcoccitones A in preparation of erythrocyte increasing drugs | |
| CN103372018B (en) | The application of Chukrasone A in the medicine of preparation increased platelets counts | |
| CN105287490A (en) | Application of Hydroxyartoflavone A in preparation of medicine for increasing red blood cells | |
| CN103393660A (en) | Application of Sarcaboside B to preparation of medicament for raising erythrocyte | |
| CN103751178B (en) | The application of Trigoxyphin K in increased platelets counts medicine | |
| CN103120685A (en) | Application of Aphanamixoid A in medicine for increasing erythrocytes | |
| CN105380952A (en) | Application of Astataricusones C in preparation of drugs for raising erythrocyte level | |
| CN103127070A (en) | Application of Eryngiolide A in medicines rising white blood cell | |
| CN105343066A (en) | Application of Herqueidiketal in preparing erythrocyte increasing medicine | |
| CN103356642B (en) | The application of Chukrasone A in the medicine preparing leukocyte increasing | |
| CN103372002A (en) | Application of Chukrasone B in preparation of medicines for increasing red blood cells | |
| CN103356555A (en) | Application of Sarcaboside A in erythrocyte-increasing medicines | |
| CN105596329A (en) | Application of Densanins B in preparation of erythrocyte rising drugs | |
| CN103120657A (en) | Application of Eryngiolide A in medicine for increasing red blood cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130911 |